There has been increasing interest in the role of aspirin in reducing the risk of colonic polyp formation and also reducing the incidence of colorectal cancer. A number of recent studies have once again addressed this issue.
A recent large-
The study of more than 600,000 people in Hong Kong divided patients into those that had been prescribed aspirin for more than six months (204,179) and those that were not taking aspirin (408,399). The average length of time that individuals was taking aspirin was 7.1 years. Patients were followed up for 14 years or until the time of their death.
Those in the aspirin group had a significantly lower incidence of colorectal cancer (2.51% versus 3.27% or, 0.76:95% CI, 0.74 – 0.79) and the mortality related to colorectal cancer (1.02% versus 1.7%; 0.59; CI, 0.56 – 0.62). The incidence of colorectal cancer started to decline after eight years of use and there was an inverse relationship between the duration of use and the incidence of colorectal cancer.
As expected there was higher incidence of gastrointestinal bleeding in patients taking aspirin (4.64% versus 2.74%) and aspirin use marginally increase the risk of mortality related to gastrointestinal bleeding (your .4% versus 0.36%). However, patients who are giving gastro protection in the form of a proton pump inhibitor or H2 antagonists had a significantly lower incidence of gastrointestinal bleeding compares the dolts who did not take gastro protection.
The authors concluded that long-
Another recent study (García Rodríguez 2017) has suggested that patients currently taking low dose aspirin have a significantly reduced risk of CRC (RR=0.66, 95% CI: 0.6 – 0.74). The reduction in risk is apparent across all ages and is unrelated to the dose. Starting low-
A number of other studies have looked at the association between the use of aspirin and the risk of a variety of cancers. A recent large-
A total of 218 studies and 309 reports were included in the meta-
These studies add to the growing list of papers that have reported on the beneficial effect of aspirin in reducing the incidence and mortality of colorectal and other cancers. Using gastro protection in the form of a PPI or H2 antagonist also reduces the incidence of GI side-
Tsoi KKF, Chan FCH, Hirai HW et al. Risk of Gastrointestinal Bleeding and Benefit from Colorectal Cancer Reduction from Long-
García Rodríguez LA, Soriano-
Qiao Y, Yang T, Gan Y, et al. Associations between aspirin use and the risk of cancers: a meta-